Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director · EXECUTIVE CHAIRMAN | November 10, 2021 | December 08, 2021 |
| CATERPILLAR INCCAT · Entity 2808 | Director | March 01, 2022 | March 02, 2022 |
| MCDONALDS CORPMCD · Entity 2849 | Director | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date November 10, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 3,092,852 |
Ending reported balance
After 2021-11-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-10 · Gift · Disposed 693 · Balance 3,103,252 Row 2 · 2021-11-12 · Gift · Disposed 10,400 · Balance 3,092,852 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 35,789 |
Reported balance
Holding disclosure · report date 2021-11-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 35,789 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 6, 2021.
CATERPILLAR INC
Report date March 01, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,382 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Tax withholding · Disposed 293 · Balance 8,382 F1: Includes adjustments for dividends accrued. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes adjustments for dividends accrued.
MCDONALDS CORP
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 23,286.12 |
Reported balance
After 2025-12-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-31 · Grant · Acquired 670.75 · Balance 23,286.12 F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4: Includes shares acquired through dividend reinvestment. |
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan").
F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation.
F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board.
F4: Includes shares acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2008 Filed Aug 13, 2008 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 202,822 | $47.10 | $9,552,916.20 |
DisclosureSEC source: 0001104659-08-052650 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · derivative · entry 30 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1 shares Expires 2008-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 92,521 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · derivative · entry 29 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 92,521 shares Expires 2008-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 44,046 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · derivative · entry 28 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 44,046 shares Expires 2008-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $58.85 | $17,655.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 24 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,361 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $58.84 | $88,260.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 23 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,661 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $58.83 | $29,415.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 22 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,161 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,000 | $58.82 | $235,280.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 21 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,661 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $58.81 | $123,501.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 20 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,661 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 32,168 | $58.80 | $1,891,478.40 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 19 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,761 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,100 | $58.79 | $417,409.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 18 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271,929 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,100 | $58.78 | $182,218.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 17 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,029 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,500 | $58.77 | $440,775.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 16 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,129 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $58.76 | $246,792.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 15 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,629 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 46,500 | $58.75 | $2,731,875.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 14 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,829 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,700 | $58.74 | $628,518.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 13 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,340,329 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $58.73 | $41,111.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 12 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,351,029 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $58.72 | $35,232.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 11 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,351,729 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $58.71 | $35,226.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 10 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352,329 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,600 | $58.70 | $563,520.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 9 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352,929 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $58.69 | $5,869.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 8 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,529 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $58.68 | $29,340.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 7 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,629 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $58.67 | $17,601.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 6 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,129 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $58.66 | $23,464.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 5 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,429 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,100 | $58.65 | $240,465.00 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 4 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,829 Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1 | $40.56 | $40.56 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 92,521 | $53.60 | $4,959,125.60 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2008 Filed Aug 8, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 44,046 | $52.55 | $2,314,617.30 |
DisclosureSEC source: 0001104659-08-051461 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 487,181 | $0.00 Strike: $57.58 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 13 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,181 Underlying: Common shares · 487,181 shares Expires 2011-02-08 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 193,509 | $0.00 Strike: $57.58 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 12 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,509 Underlying: Common shares · 193,509 shares Expires 2010-02-10 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 8,522 | $0.00 Strike: $57.58 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 11 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,522 Underlying: Common shares · 8,522 shares Expires 2009-02-11 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 558,628 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 10 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 558,628 shares Expires 2011-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 224,097 | $0.00 Strike: $44.60 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 9 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 224,097 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,128 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · derivative · entry 8 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 10,128 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 689,212 | $57.58 | $39,684,826.96 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · nonDerivative · entry 4 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,361 Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 558,628 | $45.45 | $25,388,972.25 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · nonDerivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 224,097 | $44.60 | $9,994,726.20 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2008 Filed Jul 23, 2008 21:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,128 | $42.50 | $430,417.72 |
DisclosureSEC source: 0001104659-08-047208 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 18,411 | $54.22 | $998,244.42 |
DisclosureSEC source: 0001104659-08-015215 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,720 Read SEC document |
| February 18, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,390 | $55.55 | $466,064.50 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · nonDerivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,131 Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 18,279 | $55.55 | $1,015,398.45 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,154,521 Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 530,000 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · derivative · entry 7 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,000 Underlying: common shares · 530,000 shares Expires 2018-02-14 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 176,667on 2/15/09, 176,667 on 2/15/10 and 176,666 on 2/15/11. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 135,000 | $55.56 | $7,500,600.00 |
DisclosureSEC source: 0001104659-08-011830 · a4.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,172,800 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The awards have a 5 year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,875 | $0.00 Strike: $34.77 | $0.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · derivative · entry 30 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,875 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 132,148 | $0.00 Strike: $52.55 | $0.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · derivative · entry 29 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 132,148 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 37,046 | $0.00 Strike: $47.88 | $0.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · derivative · entry 28 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 37,046 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,600 | $56.92 | $261,832.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · nonDerivative · entry 27 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,800 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $56.91 | $239,022.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · nonDerivative · entry 26 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,400 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 13,900 | $56.90 | $790,910.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · nonDerivative · entry 25 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,600 Read SEC document |
| February 08, 2008 Filed Feb 12, 2008 23:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,000 | $56.89 | $284,450.00 |
DisclosureSEC source: 0001104659-08-009497 · a4.xml · nonDerivative · entry 24 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,169,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.